Back to Journals » Pediatric Health, Medicine and Therapeutics » Volume 7

Spotlight on eltrombopag in the treatment of children with chronic immune thrombocytopenia

Authors Lambert MP

Received 18 December 2015

Accepted for publication 21 March 2016

Published 8 June 2016 Volume 2016:7 Pages 39—43

DOI https://doi.org/10.2147/PHMT.S90688

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Lucy Goodman

Peer reviewer comments 4

Editor who approved publication: Professor Laurens Holmes, Jr


Michele P Lambert,1,2
1Division of Hematology, The Children's Hospital of Philadelphia, 2Department of Pediatrics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA

Abstract: Pediatric data on the use of thrombopoietin receptor agonists are fairly limited. The recent approval of eltrombopag by the US Food and Drug Administration for children aged ≥1 year, based on data from two randomized, placebo-controlled clinical trials, may lead to the increased use of this drug in clinical practice, and therefore, it is important to have a basic understanding of the biology, pharmacokinetics, safety, and efficacy of the medication.

Keywords: ITP, pediatrics, treatment, thrombopoietin receptor agonists 

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]